ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ビンクリスチン硫酸塩

Vincristine Sulfate

HCID 249332
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
2068-78-2
標準SMILES
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
InChIKey
AQTQHPDCURKLKT-JKDPCDLQSA-N
分子式
C46H56N4O10.H2O4S
平均分子量
923 g/mol
単同位体質量
922.36702371

概要

Vincristine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.

名称と識別子

優先名称
Vincristine Sulfate
IUPAC
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid
現地名
ビンクリスチン硫酸塩
英語名
Vincristine sulfate
分子式
C46H58N4O14S
分子量
923.04

名称と別名

Vincristine sulfate2068-78-2OnkovinVCR sulfateVincristine sulphateKyocristineVincrisulLilly 37231NovopharmVincristini sulfasLeurocristine sulfateVincaleukoblastine, 22-oxo-, sulfate (1:1) (salt)
名称をさらに表示
オンコビン硫酸ビンクリスチンロイロクリスチン硫酸塩ビンクリスチン硫酸塩22-オキソビンカロイコブラスチン·硫酸塩ビンクリスチン硫酸VINCRISTINE 硫酸ビンクリスチン 硫酸塩ビンクリスチン硫酸塩 (JP17)22-オキソビンカロイコブラスチン・硫酸塩oncovinVCRvincristinVincristin SulfateVinorelbine SulfateVINCRISTINE SULFATE USPVINCRISTINE SULFATE SALT
NSC 67574VincrexLeurocristine, sulfate (1:1) (salt)Vincristine, sulfateLeurocristine, sulfateVincasar PFSNSC67574Vincristine Sulfate PFS

データベース識別子

CAS
2068-78-2
PubChem CID
249332
DTXSID
DTXSID8044331
ChEMBL
CHEMBL501867
EC Number
218-190-0

物性

構造計算による物性

極性表面積
254 Ų
水素結合供与体数
5
水素結合受容体数
16
回転可能結合数
10
重原子数
65
形式電荷
0
複雑度
1,830

実験および物理化学的性質

Solubilitygreater than or equal to 10 mg/mL at 75 °F (NTP, 1992)
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Antimitotic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point531 °F approximately (NTP, 1992)
Physical DescriptionVincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)
Collision Cross Section281 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
300 °C · 300 °C
沸点
273 · 273-281 °C
比旋光度
26 · D26 +8.5° (c = 0.8)
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
20 mg/mL · メタノール: 可溶20mg/mL
外見
凍結乾燥粉末
色
ホワイトからオフホワイト
水溶解度
1 g/100 · >=1 g/100 mL at 24 ºC
BRN
3924631 · 3924631
安定性
2 · 購入日から2年間安定です。この蒸留水溶液は、-20°C で 3 か月間保存できます。
主な用途
医薬品(低分子化合物)
InChIKey
AQTQHPDCURKLKT-HSMPTBRCNA-N
SMILES
OS(O)(=O)=O.CC[C@]1(O)CC2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)C7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]67C89)C(=O)OC)C1
EPAの化学物質情報
Vincristine sulfate (2068-78-2)

化学的性質

化学的特性Crystalline Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H300 (91.5%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationHazard Traits - Developmental Toxicity
Other Safety InformationIMAP assessments - Vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt): Human health tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 件

SYMPTOMS: The following symptoms of exposure have occurred during intravenous use. Symptoms of exposure include bone marrow depression, peripheral neuropathy, colicky abdominal pain, constipation and alopecia. Other symptoms include neuromuscular and neurological disturbances, gastrointestinal upset and leucopenia. It has caused impaired walking, convulsions, hypertension, inappropriate antidiuretic hormone (ADH) secretion, jaw pain, paresthesias in the fingers and toes, sensory impairment, headache, loss of deep tendon reflexes, parotid gland pain, optic atrophy and blindness. It has also caused acute uric acid nephropathy, myocardial infarction, ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement); laryngeal nerve paralysis causing hoarseness or cough, depression of the Achilles tendon reflex, muscle pain, weakness, motor weakness, quadriparesis, numbness and tingling of the fingers and toes, malaise, depression, psychoses, neuromyopathy, peripheral neuritis, adynamic ileus, and permanent central nervous system damage. Exposure may cause paresthesia, foot drop, ataxia, athetosis, thrombocytosis and coma. Exposure may also cause granulocytopenia, thrombocytopenia, hypoplasia of all elements of bone marrow, nausea, vomiting, anorexia, neuritic pain and motor difficulties. Other effects may include cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts, facial paralysis, diplopia and corneal hypesthesia. It may cause anemia, polyuria, dysuria, fever, tingling and numbness of the extremities, abdominal obstruction, ischemic cardiac toxicity and syndrome of hyponatremia. It may also cause diarrhea, sensory loss, slapping gait, muscle wasting, generalized sensorimotor dysfunction, paralytic ileus, abdominal cramps, rash, oral ulceration, intestinal necrosis and/or perforation, urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves; pharyngeal pain, bone pain, back pain, limb pain, myalgias, renal or adrenal disease, hypotension, dehydration, azotemia and clinical edema. Effects on the autonomic nervous system have been reported. It may cause irritation of the skin, and congenital malformation in the fetus.

Reactive GroupAlcohols and Polyols
Reactivity ProfileSensitive to hydrolysis, oxidation and heat. Incompatible with strong oxidizing agents. (NTP, 1992).
Air and Water ReactionsVery hygroscopic. Water soluble.
Hazard Classes and CategoriesAcute Tox. 2 (91.5%)

安全と保護具

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

毒性情報

Toxicity Summary · 1 件

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Carcinogen Classification · 6 件

Vincristine sulfate

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 26: (1981) Some Antineoplastic and Immunosuppressive Agents

1987

1987

Vincristine sulfate is not classifiable as to its carcinogenicity to humans (Group 3). Vincristine is part of MOPP, a combination chemotherapy regimen that is carcinogenic to humans (Group 1). (L135)

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Vincristine sulfate

vLess-DILI-concern

8

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataIVN-RAT LD<sub>50</sub> 1300 mg/kg; IPR-MUS LD<sub>50</sub> 5.2 mg/kg.

安全データ

F
8-10
wgk
3
rtecs
OH6340000
ridadr
UN 2811 6.1/PG 2
毒性
LD50 intraperitoneal in mouse: 3mg/kg
hs_code
29399990
risk_code
61-36/37/38-63-23/24/25-68-62-25
hazard_code
T
safety_code
22-24/25-53-45-37/39-26-36/37/39-36/37
hazard_class
6.1(a)
packing_group
II
Hazard Classifications
Acute Tox. 2 OralMuta. 2Repr. 2
ストレージクラス
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine. Route of Elimination: The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine. Half Life: When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.

FDA Pharmacological Classification · 2 件

VINCRISTINE SULFATE

Vinca Alkaloids [CS]; Vinca Alkaloid [EPC]

MeSH Pharmacological Classification · 2 件

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.

用途と製造

Uses · 1 件

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

応用分野 · 4 件

用途キインドールアルカロイドで す。より強い毒性を示します。β- チューブ リンに結合することにより、チューブリンの 重合を阻害し、微小管形成阻害作用を示しま す。

用途インドールアルカロイドで す。β- チューブリンに結合することにより、 チューブリンの重合を阻害し、微小管形成阻 害作用を示します。

使用Vincristine sulfate, is used as an anticancer agent, microtubule disrupter, Induces apoptosis in human lymphoma cells. Other applications include as a cell cycle arresting, apoptotic inducing alkaloid.

一般的な説明Vincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)

調製方法 · 1 件

純化方法The salt is recrystallised from MeOH. It has UV max at 220, 255 and 296nm (log  4.65, 4.21 and 4.18). It is a monoamine oxidase inhibitor and is used in cancer research [Son et al. J Med Chem 33 1845 1990, Horio et al. Proc Natl Acad Sci USA 85 3580 1988].

上流・下流製品情報

上流原料

硫酸水素ベンゼン

下流製品

ビンデシン

関連反応

7 件
反応記録を作成
HRID 437029 の反応式
HRID 437029反応物として
HRID 970265 の反応式
HRID 970265反応物として
HRID 1295536 の反応式
HRID 1295536反応物として
HRID 1296337 の反応式
HRID 1296337反応物として
HRID 1363907 の反応式
HRID 1363907反応物として
HRID 1788651 の反応式
HRID 1788651反応物として
HRID 2085903 の反応式
HRID 2085903反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート